Latest Research And Development News

Zelira Therapeutics has locked in a $650,000 loan facility secured against its anticipated FY25 R&D tax rebate, aiming to accelerate its HOPE SPV clinical trial and strengthen working capital.

AML3D Limited reports a 77% jump in US customer receipts and secures a pivotal US Navy Letter of Intent worth up to $200 million, underpinning its rapid expansion in defence manufacturing.

Kuniko Limited has applied for NOK 60 million in funding to develop a sustainable, low-emission battery metals supply chain in Norway, partnering with industry and research leaders including Stellantis.

Audeara Ltd has reported a landmark FY25 with record cash receipts of $4.9 million, driven by strong domestic sales and expanding global technology partnerships. The company’s strategic R&D and inventory build set the stage for further growth in FY26.

Adisyn Ltd has made significant strides in developing low-temperature graphene semiconductor interconnects, commissioning a new Atomic Layer Deposition system and securing a major managed IT services contract, while maintaining a strong cash position.

Antares Metals has reported promising exploration progress at its Mt Isa North project, revealing new copper mineralisation zones and multiple high-priority uranium targets. The discoveries set the stage for further drilling and resource definition.

Deep Yellow Limited reported a quarterly operating cash outflow of A$6.3 million but ended June 2025 with a strong cash position of A$217 million, providing a runway of 24 quarters at current spending levels.

Patrys Limited has announced a fully underwritten entitlement offer to raise approximately $1.77 million, aimed at funding ongoing research and development of its PAT-DX3 therapy and supporting working capital. The offer includes secondary options and shares, subject to shareholder approval, and will significantly expand the company's capital base.

Talius Group has reported a net profit of $0.37 million for Q2 2025, driven by a 6% increase in subscriptions and strategic partnerships that expand its market reach in aged care technology.

NeuroScientific Biopharmaceuticals has completed its acquisition of StemSmart technology, reporting promising clinical results in Crohn’s disease and GVHD, alongside a $3.5 million capital raise to fuel next-stage development.

Tetratherix Limited has marked a pivotal quarter with a $25 million ASX listing, an exclusive licensing agreement with Bio Optix for ophthalmic devices, and progress on FDA regulatory submissions for its prostate spacer product.

Invex Therapeutics has broadened its collaboration with Tessara Therapeutics to explore Exenatide’s potential in Alzheimer’s disease, while successfully renewing key orphan drug designations in Europe and the US.